Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.54 |
| ▸ | MGAM | O43451 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | CNR2 | P34972 | 2/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 5/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | GAA | P10253 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.43 |
| ▸ | RELA | Q04206 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9310833 | 0.79 | PIM1 (0.56) | KDM4EALDH1A1GAAKMT2A | |
| SCHEMBL16261005 | 0.79 | NPC1 (0.50) | SMN1; SMN2MAPTKMT2AMAPK1NFKB1 | |
| SCHEMBL15316356 | 0.78 | RECQL (0.47) | KDM4EMAPTALDH1A1KMT2ARAB9A | |
| SCHEMBL3143334 | 0.78 | KDM4E (0.44) | KDM4ESMN1; SMN2L3MBTL1MAPTALDH1A1 | |
| SCHEMBL28811993 | 0.77 | KDM4E (0.40) | KDM4ESMN1; SMN2L3MBTL1MAPTALDH1A1 | |
| SCHEMBL3954441 | 0.76 | MGAM (0.66) | KDM4EMGAMSMN1; SMN2CNR2HDAC8 | |
| SCHEMBL5279917 | 0.75 | DPP4 (0.39) | KMT2A | |
| Acridine SCHEMBL7872845 | 0.75 | ALDH1A1 (0.46) | KDM4EMGAML3MBTL1MAPTALDH1A1 | |
| Quinaldic Acid SCHEMBL2577620 | 0.75 | MGAM (0.70) | KDM4EMGAMSMN1; SMN2CNR2HDAC8 | |
| SCHEMBL5176927 | 0.74 | MGAM (0.63) | KDM4EMGAMSMN1; SMN2CNR2HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 116 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1461319-B1 | QUINOLINE DERIVATIVES, SYNTHESIS METHOD, AND MEDICINES CONTAINING SAID DERIVATIVES | BIOALLIANCE PHARMA (FR) | 2009-04-29 | — | — | EP | claimed |
| US-7064133-B2 | Quinoline derivatives process of synthesis and medicaments containing these derivatives | BIOALLIANCE PHARMA (FR) | 2006-06-20 | — | — | US | claimed |
| US-20040259911-A1 | Quinoline derivatives process of synthesis and medicaments containing these derivatives | INSTITUT GUSTAVE ROUSSY (FR) | 2004-12-23 | — | — | US | claimed |
| WO-2023129737-A1 | GLYCOMIMETIC LIGANDS | AVICEDA THERAPEUTICS, INC. (US) | 2023-07-06 | — | — | WO | disclosed |
| US-RE43802-E1 | α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | G.D. SEARLE LLC (US) | 2012-11-13 | — | — | US | disclosed |
| US-RE43596-E1 | α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | G.D. SEARLE LLC (US) | 2012-08-21 | — | — | US | disclosed |
| US-RE42889-E1 | α- and β- amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | G.D. SEARLE LLC (US) | 2011-11-01 | — | — | US | disclosed |
| US-7829564-B2 | α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | G.D. SEARLE LLC (US) | 2010-11-09 | — | — | US | disclosed |
| US-7531538-B2 | α- and β-Amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | G.D. SEARLE LLC (US) | 2009-05-12 | — | — | US | disclosed |
| US-20090023664-A1 | ALPHA- AND BETA-AMINO ACID HYDROXYETHYLAMINO SULFONAMIDES USEFUL AS RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE LLC (US) | 2009-01-22 | — | — | US | disclosed |
| US-7320983-B2 | α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | G.D. SEARLE LLC (US) | 2008-01-22 | — | — | US | disclosed |
| EP-0554400-A1 | RETROVIRAL PROTEASE INHIBITORS. | MONSANTO CO (US) | 1993-08-11 | — | — | EP | disclosed |
| US-5196438-A | Viricides; e.g. N-tert.butyl-decahydro-2-(2(R)-hydroxy-4-phenyl-3(S)-((N-(2 -quinolylcarbonyl)-L-asparaginyl)amino)butyl)-(4aS,8aS)-isoquinoline-3(S) -carboxamide; saquinavir and salts | HOFFMANN-LA ROCHE INC. (US) | 1993-03-23 | — | — | US | disclosed |
| EP-0512343-A2 | Amino acid derivatives and their use as anti-viral agents | F. HOFFMANN-LA ROCHE AG (CH) | 1992-11-11 | — | — | EP | disclosed |
| WO-1992008701-A1 | RETROVIRAL PROTEASE INHIBITORS | MONSANTO COMPANY (US) | 1992-05-29 | — | — | WO | disclosed |
| WO-1992008700-A1 | RETROVIRAL PROTEASE INHIBITORS | MONSANTO COMPANY (US) | 1992-05-29 | — | — | WO | disclosed |
| WO-1992008698-A1 | RETROVIRAL PROTEASE INHIBITORS | MONSANTO COMPANY (US) | 1992-05-29 | — | — | WO | disclosed |
| WO-1992008699-A1 | RETROVIRAL PROTEASE INHIBITORS | MONSANTO COMPANY (US) | 1992-05-29 | — | — | WO | disclosed |
| WO-1992008688-A1 | RETROVIRAL PROTEASE INHIBITORS | MONSANTO COMPANY (US) | 1992-05-29 | — | — | WO | disclosed |
| EP-0432695-A2 | Amino acid derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1991-06-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023664-A1 | ALPHA- AND BETA-AMINO ACID HYDROXYETHYLAMINO SULFONAMIDES USEFUL AS RETROVIRAL PROTEASE INHIBITORS | DNPEP, ASPH, PREP | KDM4E 2919/4885MGAM 272/4885SMN1; SMN2 2396/4885 |
| US-20040259911-A1 | Quinoline derivatives process of synthesis and medicaments containing these derivatives | RCOR1, RCOR3, BCOR | KDM4E 945/4885MGAM 2887/4885SMN1; SMN2 3558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.